Q&A
What happens when a histopathologist teams up with computational modelers?
Answers emerge in my chat with Nicola Palomero-Gallagher, a rare example of someone who connects the brain’s microscopic constituents and macroscopic features.
What happens when a histopathologist teams up with computational modelers?
Raising the bar for stem cell research: Q&A with Jack Mosher
New quality benchmarks for basic research involving stem cells promise to improve rigor and reproducibility, says Mosher, who helped develop the standards.
Raising the bar for stem cell research: Q&A with Jack Mosher
Magnetic stimulation for autism: Q&A with Xujun Duan
A new individualized approach to transcranial magnetic stimulation may one day be an effective treatment for social and communication difficulties, if the results from Duan’s small preliminary trial pan out.
Magnetic stimulation for autism: Q&A with Xujun Duan
Progress amid setbacks in drug trials for rare forms of epilepsy: Q&A with Justin West
Despite grave side effects, it’s vital to keep developing treatments for rare genetic forms of childhood epilepsy, says West, president of the KCNT1 Epilepsy Foundation and father of a son with the condition.
Progress amid setbacks in drug trials for rare forms of epilepsy: Q&A with Justin West
Easing sensory sensitivities in the clinic: Q&A with Leah Stein Duker
Dentist or doctor visits can overwhelm autistic children with sensory sensitivities. Occupational therapy can help, Stein Duker says.
Easing sensory sensitivities in the clinic: Q&A with Leah Stein Duker
Ruth Carper: Imaging the aging brain in autistic adults
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
Ruth Carper: Imaging the aging brain in autistic adults
The future of autism therapies: A conversation with Lilia Iakoucheva and Derek Hong
If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.
The future of autism therapies: A conversation with Lilia Iakoucheva and Derek Hong
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Mapping genetic influences on the infant brain: A chat with Rebecca Knickmeyer
Researchers know little about the ways genetic variants affect development in the infant brain. Knickmeyer, who launched the Organization for Imaging Genomics in Infancy, has spent the past five years trying to close the gap.
Mapping genetic influences on the infant brain: A chat with Rebecca Knickmeyer
Filling autism knowledge gaps in Latin America: Q&A with Cecilia Montiel-Nava
Countries across Latin America and the Caribbean struggle to collect data on autism, but Cecilia Montiel-Nava and the Latin American Autism Spectrum Network are beginning to change that.
Filling autism knowledge gaps in Latin America: Q&A with Cecilia Montiel-Nava
Explore more from The Transmitter
New method reignites controversy over brain clearance during sleep
Tracers injected directly into mouse brain tissue instead of the cerebrospinal fluid show that brain clearance slows during sleep and under anesthesia, according to a study published last week—but proponents of the glymphatic system take issue with the technique.
New method reignites controversy over brain clearance during sleep
Tracers injected directly into mouse brain tissue instead of the cerebrospinal fluid show that brain clearance slows during sleep and under anesthesia, according to a study published last week—but proponents of the glymphatic system take issue with the technique.
Cannabis may be rescheduled–what does it mean for neuroscience?
The drug could become much easier to access, increasing the number of researchers who can work with it and the manufacturers who can produce it.
Cannabis may be rescheduled–what does it mean for neuroscience?
The drug could become much easier to access, increasing the number of researchers who can work with it and the manufacturers who can produce it.
How inbreeding almost tanked an up-and-coming model of Alzheimer’s disease
But new genetic analyses and behavioral assays have made the Chilean degu a viable model again, researchers say.
How inbreeding almost tanked an up-and-coming model of Alzheimer’s disease
But new genetic analyses and behavioral assays have made the Chilean degu a viable model again, researchers say.